Trials
3 active
5 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- SARS-CoV-2 (3 trials)
- Main trialPhase 4
- “The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1283 and mRNA-1273 (variant formulations) within the current epidemiological environment”In the company’s words, NCT07863635 on ClinicalTrials.gov
- Other names
- mNEXSPIKE
Other drugs for SARS-CoV-2
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up3
- 11 DecPhase 4 trial completes · ClinicalTrials.gov
- 16 Jun 2027Phase 4 trial completes · ClinicalTrials.gov
- 30 Aug 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 11 Dec 2026 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | |
| Phase 4Active, not recruiting | 16 Jun 2027 | A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | |
| Phase 2Recruiting | 30 Aug 2029 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age | |
| Phase 2Completed | 23 Mar 2023 | A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters | |
| Phase 1Completed | 25 Jul 2023 | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026